SynthesisCardiovascular and interventional radiology2026
Lumbar Sympathectomy in Chronic Limb-Threatening Ischaemia: Current Trends and Future Directions.
Synthesis in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumbar sympathectomy (LS) remains a therapeutic option for patients with chronic limb-threatening ischaemia not amenable to revascularisation. A systematic review was performed with sixteen total studies included. Retroperitoneoscopic LS was safer than open LS, with a shorter hospital stay. Chemical LS showed comparable efficacy with fewer complications and a reduced admission time. Irrespective of modality, LS provided consistent pain relief, wound healing, and quality-of-life improvement, though haemodynamic improvements were inconsistent. Limb salvage rates were generally favourable with no procedure-associated mortality. LS remains a niche, palliative intervention that may offer meaningful symptomatic relief when revascularisation is not feasible. Further long-term prospective studies measuring key haemodynamic parameters are required to refine patient selection and ascertain the potential of LS in modern chronic limb-threatening ischaemia management.
Indexed as
Identifiers
41254237What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.